No recommendations for Covid booster dose by SEC: Report

Dec 11, 2021

New Delhi [India], December 11 (ANI): The Subject Expert Committee (SEC) under Central Drugs Standard Control Organization (CDSCO) has said COVID-19 that booster doses cannot be recommended without clinical trials.

The SEC was reviewing the application of the Serum Institute of India (SII) for the booster dose in a meeting that took place on Friday.

The panel has sought additional data from the SII and would be doing another meeting.

Amid the emergence of the new COVID variant Omicron, the SII had sought approval to administer the booster dose of its Covishield vaccine on the basis of adequate stock of the jab and rising demand for the booster shots.

Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, had at the time cited that the UK's Medicines and Healthcare Products Regulatory Agency has already approved the booster dose of AstraZeneca ChAdOx1 nCoV-19 vaccine. "People of our country, as well as citizens of other countries who have already been fully vaccinated with two doses of Covishield, are also continuously requesting our firm for booster dose," Singh had stated in an application submitted before the Drugs Controller General of India (DGCI).

Many experts have also recommended a booster dose in India especially after the emergence of the new COVID-19 variant Omicron. But the government has not taken any decision so far.

However, the National Technical Advisory Group on Immunization (NTAGI) also conducted a virtual meeting regarding the additional doses of COVID-19 vaccines in India, but the meeting resulted in no consensus over the issue.

A clarification statement released by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) has also said that they have never recommended a booster dose.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance. We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard .

Digital Editor

Related Posts